Literature DB >> 20652981

Combined therapy for thyroid squamous cell carcinoma.

Filip Yves F L De Vos1, Aniel Sewnaik, J Hans W de Wilt, Ernst J Smid, Michael A den Bakker, Esther van Meerten.   

Abstract

BACKGROUND.: Squamous carcinoma of the thyroid is a rare aggressive disease, resulting in poor prognosis. METHODS AND RESULTS.: We combined cisplatin with paclitaxel on a weekly basis as induction therapy, achieving a high cumulative dose, in a patient with squamous cell tumor of the thyroid with arterial encasement. After surgery, pathologic examination confirmed a complete resection of the primary tumor with clear margins, revealing a successful induction treatment with chemotherapy. CONCLUSIONS.: Our patient now has a recurrence-free survival of >20 months, longer than the mean survival described in the literature.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652981     DOI: 10.1002/hed.21484

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  4 in total

1.  Primary squamous cell carcinoma of thyroid: a case report and review of literature.

Authors:  Mutahir A Tunio; Mushabbab Al Asiri; Mosa Fagih; Rashad Akasha
Journal:  Head Neck Oncol       Date:  2012-03-27

2.  Primary squamous cell carcinoma of the thyroid: Case report and systematic review of the literature.

Authors:  Florian Struller; Moritz Senne; Claudius Falch; Andreas Kirschniak; Alfred Konigsrainer; Sven Muller
Journal:  Int J Surg Case Rep       Date:  2017-06-13

3.  Treatment optimization and prognostic considerations for primary squamous cell carcinoma of the thyroid.

Authors:  Wenlong Wang; Qianhui Ouyang; Chaoyang Meng; Lanyu Jing; Xinying Li
Journal:  Gland Surg       Date:  2019-12

4.  Primary Squamous Cell Carcinoma of the Thyroid Gland.

Authors:  Mohd-Irman-Shah Ibrahim; Yusri-Rahimi Jusoh; Nurul-Nadhihah Adam; Irfan Mohamad
Journal:  Iran J Otorhinolaryngol       Date:  2018-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.